News & Events
ASX Announcement - Clinical Trial Update
01 / 09 / 2005
Sydney, Australia: Sunshine Heart, Inc., (ASX: SHC) today provided an update on the C-Pulse device recently implanted in a New Zealand patient. The device was successfully implanted, the patient left hospital after only 9 days and showed very positive progress at one month.…
Bronchitol Cystic Fibrosis Trial Results Positive
31 / 08 / 2005
BronchitolT was well tolerated and demonstrated statistically significant improvement in lung function relative to placebo. Pharmaxis (ASX:PXS, NASDAQ:PXSL) is pleased to announce results from its Phase II trial, DPM-CF-201, in patients with cystic fibrosis. …
Cortical Pty Ltd Presents MIF Antagonist Data at World Congress on Inflammation
29 / 08 / 2005
Melbourne-based discovery research and development company Cortical Pty Ltd will be presenting pre-clinical data on its anti-inflammatory compound COR100140 at the 7th World Congress on Inflammation held in Melbourne, Australia 20-24 August 2005. Cortical has developed small…
CogState Signs Agreement with ALZA Corporation
25 / 08 / 2005
CogState Ltd (ASX:CGS) announces today that they have signed an agreement with ALZA Corporation, a member of the Johnson and Johnson group of companies, to provide cognitive testing services for a phase I clinical study. The total revenue under the agreement will be…
Pharmaxis Lists ADRs on NASDAQ
23 / 08 / 2005
Pharmaxis Ltd (ASX:PXS), announced today that it has received approval from NASDAQ to list its American Depositary Receipts (ADRs) on the NASDAQ National Market under the symbol PXSLY (CUSIP number: 71715J 10 5). No new shares will be issued in conjunction with the listing and one ADR will…
CogState Signs Agreement in "Smart Foods" / Complementary Medicine Sector with Total Revenue of $306,000
22 / 08 / 2005
CogState Ltd (ASX:CGS) announces today that they have signed an agreement with a European food-products company to study the effect of certain of their food products on cognitive function. The total revenue under the agreement will be $306,000. CogState has previously…
Novasys Medical, Inc. Receives FDA Clearance for the Renessa(TM) System
03 / 08 / 2005
Novel Non-Surgical Approach to Treat Female Stress Urinary Incontinence NEWARK, Calif., /PRNewswire/ -- Novasys Medical, Inc. announced today that its Renessa(TM) System has been cleared for marketing by the United States Food and Drug Administration (FDA) for the treatment…
Successful second Sunshine C-Pulse implant
01 / 08 / 2005
Sydney, Australia In a continuation of a 10-patient, long-term pilot clinical trial, a second person with heart failure has been successfully implanted with the C-Pulse counterpulsation pump from Sunshine Heart, Inc (ASX: SHC). As with the first C-Pulse…
Update on Clinical Trial Program
29 / 07 / 2005
Sydney, Australia - Medical investigators at Auckland City Hospital today provided an update on the long-term pilot clinical trial of Sunshine Heart's (ASX: SHC) C-Pulse heart assist device. Sadly, the first patient who received the C-Pulse device on May 04, 2005 died eleven and a…
SPINIFEX SECURES $3.25 M INVESTMENT TO DEVELOP PAIN THERAPY
26 / 07 / 2005
A pain drug development company spun out of the University of Queensland has received a $3.25 million investment commitment to develop its innovative new pain therapy. Spinifex Pharmaceuticals, an emerging biotechnology company specialising in the development of therapeutics…
Pharmaxis Receives Approval to Begin Canadian Cystic Fibrosis Trial
21 / 07 / 2005
Pharmaxis Ltd (ASX:PXS) announced today that Health Canada has granted it approval to conduct a clinical trial of Bronchitol in patients with cystic fibrosis. The approval, granted following the acceptance of product information, manufacturing and safety data and trial…
US FDA Grants Bronchitol Orphan Drug Status for Treatment of Cystic Fibrosis
20 / 07 / 2005
Pharmaxis (ASX:PXS) announced today that the United States Food and Drug Administration (FDA) has expanded the orphan drug designation for the company's product BronchitolT. Bronchitol has been granted the additional indication of facilitating mucus clearance in patients with cystic…
CogState Tops $1 Million in Sales for 2004-05 (Up 420% on Previous Year) from Contracts with Companies Such as Pfizer & Roche
04 / 07 / 2005
Melbourne-based biotechnology company, CogState, exceeded $1 million in sales for the 2004-2005 year - reinforcing Steve Burrill's prediction at BIO 2005 that the testing of memory and cognition "will be the single largest market of tomorrow." CogState's sales - an…
Prof Ron Sekel Awarded OAM for Services to Health
14 / 06 / 2005
Portland Orthopaedics Limited is proud to announce that local Orthopaedic surgeon, Prof. Ron Sekel was awarded the Medal of the Order of Australia in the Queens Birthday awards announced yesterday for his services to health. Prof Sekel has practiced as an Orthopaedic surgeon at the…
Leading Australian Heart Surgeon Joins Sunshine Heart Inc Medical Advisory Board
08 / 06 / 2005
Sunshine Heart, Inc., (ASX: SHC) today announced that Professor Don Esmore has accepted its invitation to join the Company's medical advisory board. Donald Rohrbaugh, CEO of Sunshine Heart, Inc., commented "We are delighted that Don Esmore has agreed to join our medical…
Study shows Promics' Second Generation Drug Active in Inflammatory Bowel Disease
02 / 06 / 2005
Brisbane, Australia Research conducted by Promics' scientists in its Brisbane laboratories has demonstrated a marked effect of a second generation orally active C5a antagonist (PMX205) in a widely used animal model of inflammatory bowel disease (IBD). …
Phenomix Closes Series B Financing at $40 Million
24 / 05 / 2005
San Diego, CA - Phenomix Corporation, a drug discovery and development company, announced today the closing of a $40 million private placement of its Series B preferred stock, bringing the total amount raised since inception to $65.5 million. New investors JPMorgan Partners and Delphi…
GBS BioVentures III
10 / 05 / 2005
GBS Venture Partners, Australia's leading life science specialist venture capital investor, this week completed the close of its GBS BioVentures III Fund, with $145 million. Geoff Brooke of GBS said "We were delighted with the level of interest in the fund and thrilled to close well over…
Sunshine Heart successful first implant of C-Pulse heart failure device
09 / 05 / 2005
In summary: 56 year old man in Class III heart failure was successfully implanted with the first non-blood contacting C-Pulse device for the treatment of heart failure. C-Pulse is designed to meet a major demand for better treatment options for people in moderate…
Patient in long term heart failure receives new hope through C-Pulse heart failure device
09 / 05 / 2005
A 56-year old New Zealand man has become the first person to be implanted with the C-Pulse heart device developed by Australian company Sunshine Heart, Inc. The world first operation took place at Auckland City Hospital on 4th May 2005 with doctors today releasing details…
Cystic Fibrosis Trial Reaches Target Recruitment
29 / 04 / 2005
Pharmaxis (ASX:PXS) announced today that the recruitment target has been reached for its Phase II clinical trial of Bronchitol in patients with cystic fibrosis. The study was designed to evaluate the effects of inhaled Bronchitol compared with a placebo. The trial…
Melbourne researchers develop safer and more effective "aspirin"
18 / 04 / 2005
Monash University researchers and staff of the Melbourne-based biotechnology company Cerylid Biosciences Ltd, have discovered and developed a new class of anti-clotting drugs that appears to be more effective than aspirin at preventing disease-causing blood clots and has fewer side…
CogState Awarded Patent for Innovative Psychological Testing Techniques
07 / 04 / 2005
Australian biotech, CogState, has announced the granting of the company's first patent covering it scomputerized neuropsychological testing techniques. CogState Limited (ASX: CGS) announced today that IP Australia has awarded the company a patent for its "Psychological Testing Method…
Dynamic Hearing Signs Licence Agreement with Gennum Corporation, Consolidating Global Markets for Australian Technology
07 / 04 / 2005
Dynamic Hearing Australia has signed a licence agreement with Canadian-based Gennum Corporation, to supply ADRO technology for Advanta, a new high-end amplifier for hearing instruments. In a non-exclusive agreement, Dynamic Hearing has licenced the technology for an initial three year…